Moreover, RNA-sequencing analysis identified a remarkable downregulation of IL-17 signaling pathways in ADSC-treated mice, indicating that the therapeutic effect of ADSCs on AD may be attributable to downregulating IL-17 secretion by Th17 cells. This evidence concerns the gene IL17A and Alzheimer disease.